Led by Former Lilly Exec, Apexian Out to Tackle Pancreatic Cancer

Pancreatic cancer’s standard of care includes a drug that does not help most people diagnosed with the disease. Gemcitabine (Gemzar) works in only about 10 percent of patients, says Steve Carche…
Read the full story: Xconomy